Federated Hermes Inc. Lowers Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Federated Hermes Inc. reduced its holdings in Lantheus Holdings, Inc. by 1.1%, ending the first quarter with approximately **312,161 shares** valued at **$30.5 million**.
• Several institutional investors such as Janus Henderson Group PLC and Farallon Capital Management significantly increased their stakes in Lantheus during the last quarter, indicating a strong interest in the company.
• Lantheus reported a **loss** in its latest earnings with **$1.53 EPS**, missing estimates, and revenue of **$372.76 million**, which also fell short of expectations.

Federated Hermes Inc. trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 312,161 shares of the medical equipment provider's stock after selling 3,557 shares during the quarter. Federated Hermes Inc. owned 0.46% of Lantheus worth $30,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. Mackenzie Financial Corp grew its stake in Lantheus by 129.2% during the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider's stock valued at $48,550,000 after purchasing an additional 280,381 shares during the last quarter. Serenus Wealth Advisors LLC purchased a new stake in Lantheus during the 1st quarter valued at about $212,000. TD Asset Management Inc grew its stake in Lantheus by 1,028.0% during the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock valued at $66,623,000 after purchasing an additional 622,100 shares during the last quarter. Assetmark Inc. grew its stake in Lantheus by 46.9% during the 1st quarter. Assetmark Inc. now owns 101,431 shares of the medical equipment provider's stock valued at $9,900,000 after purchasing an additional 32,372 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in Lantheus by 21.4% during the 1st quarter. Cetera Investment Advisers now owns 28,362 shares of the medical equipment provider's stock valued at $2,768,000 after purchasing an additional 5,004 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH traded down $0.62 during mid-day trading on Friday, reaching $70.57. The company had a trading volume of 943,059 shares, compared to its average volume of 1,017,600. The stock has a market capitalization of $4.88 billion, a P/E ratio of 20.05 and a beta of 0.14. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.21. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The stock has a 50 day moving average of $77.65 and a two-hundred day moving average of $87.94.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the previous year, the company earned $1.69 EPS. Lantheus's revenue was up .8% compared to the same quarter last year. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on LNTH shares. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley lowered their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.20.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.